For everyday people investing in biotechnology, the promise of a breakthrough cancer treatment is both inspiring and financially significant. However, a new securities class action lawsuit alleges that ImmunityBio, Inc. (NASDAQ: IBRX) and its leadership misled the public about the true capabilities of its lead drug, Anktiva.
The lawsuit follows a sharp decline in the company’s stock price after federal regulators stepped in to correct what they called “false or misleading” claims. If you invested in ImmunityBio and saw the value of your shares plummet, you may be eligible to participate in a legal effort to hold the company accountable for these alleged misrepresentations
The Allegations: Did ImmunityBio Overstate a “Cancer Cure”?
The core of this legal dispute centers on promotional materials released by ImmunityBio between January 19, 2026, and March 24, 2026. During this period, the lawsuit alleges that the company’s Executive Chairman, Dr. Patrick Soon-Shiong, materially misrepresented the capabilities of Anktiva in a podcast and a television advertisement.
Specifically, the complaint points to statements suggesting that Anktiva—an immunotherapy approved for a specific type of non-muscle invasive bladder cancer—could actually treat “all cancers” and function as a “cancer vaccine” to prevent disease. The lawsuit argues that by blurring the lines between future aspirations and current medical approval, the company artificially inflated its stock price at the expense of everyday investors
FDA Intervention: Regulators Flag Misleading Promotional Claims
The situation reached a breaking point on March 24, 2026, when a formal warning letter from the U.S. Food and Drug Administration (FDA) was publicized. The FDA’s Office of Prescription Drug Promotion (OPDP) determined that the company’s marketing created a “misleading impression” about the drug’s safety and efficacy.
The FDA’s warning highlighted several major concerns:
-
Unapproved Uses: Suggesting Anktiva could treat all cancers or prevent cancer in people exposed to radiation.
-
Incorrect Administration: Describing the drug as a “single jab” or subcutaneous injection, despite its approval only for intravesical use (directly into the bladder).
-
Risk Omissions: Failing to provide a balanced view of safety risks, such as urinary tract infections or musculoskeletal pain.
-
Prior Warnings: The FDA noted it had sent “Untitled Letters” in September 2025 and January 2026 raising similar concerns, yet the misleading promotions allegedly continued
Legal Context: Holding Corporations Accountable for Securities Fraud
Securities laws are designed to ensure that when companies speak to the public, they tell the truth. Under the Private Securities Litigation Reform Act (PSLRA), “everyday people” who buy stock have a right to rely on the accuracy of a company’s public statements. When a corporation allegedly hides risks or exaggerates the efficacy of its products to boost its share price, it is considered securities fraud.
In this case, the plaintiffs argue that ImmunityBio violated these federal laws by failing to disclose that their promotional claims were scientifically unsupported and likely to trigger regulatory action. By bringing a class action, investors can pool their resources to stand up to a multi-billion dollar biotech firm and seek to recover their lost capital.
Next Steps: How to Protect Your Rights
When a biotech company’s claims are challenged by a federal warning, investors are often the ones left with the financial consequences. Here is how you can take action today:
-
Gather Your Records: Find your brokerage statements showing the dates and prices of your IBRX purchases between January and March 2026.
-
Calculate Your Losses: Determine the total impact the March 24 price drop had on your portfolio.
-
Connect With an Experienced Attorney: You can reach out to a firm specializing in shareholder rights to discuss your specific situation.At ClassActionU.org, we empower people to demand transparency from the companies they invest in.
-
There is no cost or obligation to reach out and learn more about your legal options. By staying informed and taking action, you help ensure that corporations are held to the highest standards of honesty.
